Results 61 to 70 of about 2,847,915 (169)

Augmented epigenetic repression of hepatitis B virus covalently closed circular DNA by interferon-α and small-interfering RNA synergy

mBio
The persistence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is a key obstacle for HBV cure. This study aims to comprehensively assess the effect of interferon (IFN) and small-interfering RNA (siRNA) combination on the cccDNA ...
Kongying Hu, Wenjing Zai, Mingzhu Xu, Haiyu Wang, Xinluo Song, Chao Huang, Jiangxia Liu, Juan Chen, Qiang Deng, Zhenghong Yuan, Jieliang Chen   +10 more
doaj   +1 more source

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

MedComm, Volume 7, Issue 7, July 2026.
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang, Yiqiong Song, Ziyang Wang, Ke Chao, Lifeng Li, Xu Zhang, Xiaoran Duan, Chenglong Yu, Ruyue Xue, Jie Zhao   +9 more
wiley   +1 more source

Applications of CRISPR/Cas as a Toolbox for Hepatitis B Virus Detection and Therapeutics

Viruses
Hepatitis B virus (HBV) infection remains a significant global health challenge, leading to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC).
Anuj Kumar, Emmanuel Combe, Léa Mougené, Fabien Zoulim, Barbara Testoni   +4 more
doaj   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

PRKDC promotes hepatitis B virus transcription through enhancing the binding of RNA Pol II to cccDNA

Cell Death and Disease, 2022
Hepatitis B virus infection remains a major health problem worldwide due to its high risk of liver failure and hepatocellular carcinoma. Covalently closed circular DNA (cccDNA), which is present as an individual minichromosome, serves as the template for
Yao Fan, Yi Liang, Yu Liu, Hui Fan
doaj   +1 more source

Evolving Strategies in HBV Management: Insights From Updated International Guidelines

Hepatology Research, Volume 56, Issue 7, Page 1070-1078, July 2026.
Recent updates to WHO (2024), EASL (2025), and AASLD (2025) hepatitis B guidelines reflect divergent strategies, ranging from simplified public health‐oriented treatment expansion to biomarker‐driven precision medicine. Despite differences in treatment eligibility and nucleos(t)ide analogue discontinuation, all guidelines converge on early intervention
Masaru Enomoto, Grace Lai‐Hung Wong, Rui Huang, Mindie H. Nguyen   +3 more
wiley   +1 more source

Liver Transplantation for HBV‐Related Disease in France: NUC Type Before LT Is Associated With Patient Survival

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background & Aims Liver transplantation (LT) is indicated for liver complications related to hepatitis B virus (HBV) infection: acute liver failure (ALF), decompensated cirrhosis or hepatocellular carcinoma (HCC). The present study aimed to describe and evaluate patient survival after LT for HBV‐related disease in France and identify the ...
Isaure Bienvenue, Olivier Roux, Audrey Coilly, Armand Abergel, Teresa Antonini, Thierry Artzner, Olivier Boillot, Faiza Chermak, Filomena Conti, Sébastien Dharancy, Christophe Duvoux, Laure Elkrief, Marwin Farrugia, Claire Francoz, Baptiste Giguet, Jean Hardwigsen, Pauline Houssel‐Debry, Marie‐Noëlle Hilleret, Nassim Kamar, Marianne Latournerie, Magdalena Meszaros, Sylvie Radenne, Bruno Roche, Ephrem Salamé, Delphine Verhoeven‐Weil, Didier Samuel, Fabien Zoulim, Jérôme Dumortier, François Villeret   +28 more
wiley   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 170-188, June 2026.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Scavenger Receptor Class F Member 2: An Intracellular Receptor Escorting Hepatitis B Virus From Endosome to Nuclear Pore

MedComm – Future Medicine, Volume 5, Issue 3, September 2026.
Yujing Ng, Lin Du, Huahao Fan
wiley   +1 more source

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan

Hepatology Research, Volume 56, Issue 6, Page 944-955, June 2026.
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki, Satoshi Shirahama, Takahiro Yasaka, Shota Yamaguchi, Masashi Mizokami, Junko Tanaka, Hiroaki Okamoto, Hiroshi Yatsuhashi   +7 more
wiley   +1 more source